FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 69414

Company■ Unclear/unknown

New Phase 3 trial: Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne — Sagimet Biosciences Inc.

KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-07 12:00 UTC
LAST UPDATE2026-10-07 12:00 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

New Phase 3 acne trial start is a pipeline milestone but years from revenue.

Early-stage catalyst, limited near-term impact
CATALYST TO WATCH

Interim enrollment and safety data

MAIN RISK

Trial may fail or delay

FULL DISPATCH

Sponsor: Sagimet Biosciences Inc.; Status: Recruiting; Conditions: Acne Vulgaris; Interventions: Denifanstat, Placebo; Enrollment: 800 (estimated); First posted: 2026-10-07; NCT: NCT07863193

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-07 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.